VTWO - Vanguard Russell 2000 ETF

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
134.63
-0.20 (-0.15%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close134.83
Open134.91
Bid133.86 x 900
Ask142.70 x 1200
Day's Range134.58 - 135.30
52 Week Range107.77 - 136.70
Volume50,425
Avg. Volume60,963
Net Assets2.47B
NAV131.06
PE Ratio (TTM)N/A
Yield1.14%
YTD Return7.81%
Beta (3y)1.08
Expense Ratio (net)0.15%
Inception Date2010-09-20
Trade prices are not sourced from all markets
  • 6 Small-Cap ETFs at 52-Week High With More Room to Run
    Zacks25 days ago

    6 Small-Cap ETFs at 52-Week High With More Room to Run

    Trade war fears have taken Wall Street in its grip and these small-cap ETFs are enjoying high momentum.

  • 5 Market-Beating Small-Cap ETFs Trading at New Highs
    InvestorPlace2 months ago

    5 Market-Beating Small-Cap ETFs Trading at New Highs

    Wall Street has been on a roller-coaster ride this year. Yet, the small-cap segment of the broader market has been outperforming, defying extremely volatility. This is especially true as the Russell 2000 is nearing its record levels with just less than 1% away from its peak.Source: ShutterstockWhy Small Caps?

  • Investopedia3 months ago

    The Role of Securities Lending in ETF Returns

    ETFs produce significant revenue by lending out securities, but there are risks associated with the practice.

  • Where Atara Biotherapeutics Stands This January: Analyst Ratings
    Market Realist5 months ago

    Where Atara Biotherapeutics Stands This January: Analyst Ratings

    Of the six analysts covering Atara Biotherapeutics in January 2018, four analysts have given the stock a “buy” or a higher rating, while two analysts have given it a “hold” rating. By comparison, of the 26 analysts covering Amgen (AMGN) in January 2018, 12 analysts have given the company a “buy” or a higher rating, while 14 analysts have given it a “hold” rating. Of the 31 analysts covering Celgene (CELG) in January 2018, 17 analysts have given the stock a “buy” or a higher rating, while 13 analysts have given the stock a “hold” rating, and only one analyst has given it a “sell” rating.

  • Does Accelerate Diagnostics’ Financial Performance Bode Well?
    Market Realist6 months ago

    Does Accelerate Diagnostics’ Financial Performance Bode Well?

    How Is Accelerate Diagnostics Positioned at the Start of 2018? The net sales of Accelerate Diagnostics (AXDX) increased from $24,000 in 3Q16 to $828,000 in 3Q17. For fiscal 2017, Accelerate Diagnostics is expected to report revenues of $5 million, while peers Becton Dickinson (BDX), Bruker (BRKR), and Thermo Fisher Scientific (TMO) are expected to report revenues of $12 billion, $1.7 billion, and $20.5 billion, respectively.